Literature DB >> 9105735

Type 3 inositol 1,4,5-trisphosphate receptor and capacitative calcium entry.

J W Putney1.   

Abstract

It is well established that depletion of intracellular stores of calcium can activate calcium influx across the plasma membrane, a process known as "capacitative calcium entry'. Recent research and reviews have focussed on homologs of the Drosophila mutant, trp, as candidates for the channels underlying this phenomenon. However, there is recent evidence that the type 3 inositol 1,4,5-trisphosphate {(1,4,5)IP3} receptor can also function as a capacitative calcium entry channel, specifically: (i) in some cell types, the properties of Ca2+ store depletion-activated currents and channels resemble those of an (1,4,5)IP3 receptor;(ii) in these same cell types, (1,4,5)IP3 directly activates channels in the plasma membrane (including in one study, the same channels activated by depletion of Ca2+ stores); and (iii) expression of the type 3 receptor in Xenopus oocytes resulted in the association of this receptor with the plasma membrane, and facilitation of Ca2+ entry across the plasma membrane. The type 3 receptor may represent one type of capacitative calcium entry channel expressed in some cell types and, in other cell types, channels with markedly different properties (i.e. trp) may carry out this function. Furthermore, as there is little, if any, homology between the IP3 and trp protein families, this may represent an example of convergent evolution of function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105735     DOI: 10.1016/s0143-4160(97)90050-6

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  20 in total

Review 1.  Calcium channels in lymphocytes.

Authors:  G Grafton; L Thwaite
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

2.  Molecular cloning and immunolocalization of a novel vertebrate trp homologue from Xenopus.

Authors:  L K Bobanovic; M Laine; C C Petersen; D L Bennett; M J Berridge; P Lipp; S J Ripley; M D Bootman
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

Review 3.  Regulatory activity of polyunsaturated fatty acids in T-cell signaling.

Authors:  Wooki Kim; Naim A Khan; David N McMurray; Ian A Prior; Naisyin Wang; Robert S Chapkin
Journal:  Prog Lipid Res       Date:  2010-02-20       Impact factor: 16.195

Review 4.  Calcium signaling in vasopressin-induced aquaporin-2 trafficking.

Authors:  Lavanya Balasubramanian; James S K Sham; Kay-Pong Yip
Journal:  Pflugers Arch       Date:  2007-10-24       Impact factor: 3.657

Review 5.  Receptor-activated Ca2+ inflow in animal cells: a variety of pathways tailored to meet different intracellular Ca2+ signalling requirements.

Authors:  G J Barritt
Journal:  Biochem J       Date:  1999-01-15       Impact factor: 3.857

6.  Differential regulation of types-1 and -3 inositol trisphosphate receptors by cytosolic Ca2+.

Authors:  T J Cardy; D Traynor; C W Taylor
Journal:  Biochem J       Date:  1997-12-15       Impact factor: 3.857

7.  Histones and basic polypeptides activate Ca2+/cation influx in various cell types.

Authors:  A Gamberucci; R Fulceri; P Marcolongo; W F Pralong; A Benedetti
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

8.  Chemical inhibitors of the calcium entry channel TRPV6.

Authors:  Christopher P Landowski; Katrin A Bolanz; Yoshiro Suzuki; Matthias A Hediger
Journal:  Pharm Res       Date:  2010-11-06       Impact factor: 4.200

9.  Sources of calcium in agonist-induced contraction of rat distal colon smooth muscle in vitro.

Authors:  Hua Zhou; De-Hu Kong; Qun-Wan Pan; Hai-Hua Wang
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

10.  Glioblastoma cells express functional cell membrane receptors activated by daily used medical drugs.

Authors:  Susanne A Kuhn; Ulrike Mueller; Uwe-K Hanisch; Christian R A Regenbrecht; Ilona Schoenwald; Michael Brodhun; Hartwig Kosmehl; Christian Ewald; Rolf Kalff; Rupert Reichart
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.